|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schirren R, Reim D and Novotny AR:
Adjuvant and/or neoadjuvant therapy for gastric cancer cancer? A
perspective review. Ther Adv Med Oncol. 7:39–48. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ito S, Oki E, Nakashima Y, Ando K, Hiyoshi
Y, Ohgaki K, Saeki H, Morita M, Sakaguchi Y and Maehara Y: Clinical
significance of adjuvant surgery following chemotherapy for
patients with initially unresectable stage IV gastric cancer.
Anticancer Res. 35:401–406. 2015.PubMed/NCBI
|
|
5
|
Lane DP and Crawford LV: T antigen is
bound to a host protein in SV40-transformed cells. Nature.
278:261–263. 1979. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stegh AH: Targeting the p53 signaling
pathway in cancer therapy-the promises, challenges and perils.
Expert Opin Ther Targets. 16:67–83. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Busuttil RA, Zapparoli GV, Haupt S,
Fennell C, Wong SQ, Pang JM, Takeno EA, Mitchell C, Di Costanzo N,
Fox S, et al: Role of p53 in the progression of gastric cancer.
Oncotarget. 5:12016–12026. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoshimura A, Sugihara H, Ling ZQ, Peng DF,
Mukaisho K, Fujiyama Y and Hattori T: How wild-type TP53 is
inactivated in undifferentiated-type gastric carcinomas: Analyses
of intratumoral heterogeneity in deletion and mutation of TP53.
Pathobiology. 73:40–49. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chan WM and Poon RY: The p53 Isoform
Deltap53 lacks intrinsic transcriptional activity and reveals the
critical role of nuclear import in dominant-negative activity.
Cancer Res. 67:1959–1969. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Courtois S, Verhaegh G, North S, Luciani
MG, Lassus P, Hibner U, Oren M and Hainaut P: DeltaN-p53, a natural
isoform of p53 lacking the first transactivation domain,
counteracts growth suppression by wild-type p53. Oncogene.
21:6722–6728. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marcel V, Perrier S, Aoubala M, Ageorges
S, Groves MJ, Diot A, Fernandes K, Tauro S and Bourdon JC: Δ160p53
is a novel N-terminal p53 isoform encoded by Δ133p53 transcript.
FEBS Lett. 584:4463–4468. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chambers SK and Martinez JD: The
significance of p53 isoform expression in serous ovarian cancer.
Future Oncol. 8:683–686. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Philipova T, Baryawno N, Hartmann W,
Pietsch T, Druid H, Johnsen JI and Ekström TJ: Differential forms
of p53 in medulloblastoma primary tumors, cell lines and
xenografts. Int J Oncol. 38:843–849. 2011.PubMed/NCBI
|
|
14
|
Goldschneider D, Horvilleur E, Plassa LF,
Guillaud-Bataille M, Million K, Wittmer-Dupret E, Danglot G, de Thé
H, Bénard J, May E and Douc-Rasy S: Expression of C-terminal
deleted p53 isoforms in neuroblastoma. Nucleic Acids Res.
34:5603–5612. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wei J, Noto J, Zaika E, Romero-Gallo J,
Correa P, El-Rifai W, Peek RM and Zaika A: Pathogenic bacterium
Helicobacter pylori alters the expression profile of p53 protein
isoformsand p53 response to cellular stresses. Proc Natl Acad Sci
USA. 109:pp. E2543–E2550. 2012; View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei J, O'Brien D, Vilgelm A, Piazuelo MB,
Correa P, Washington MK, El-Rifai W, Peek RM and Zaika A:
Interaction of Helicobacter pylori with gastric epithelial cells is
mediated by the p53 protein family. Gastroenterology.
134:1412–1423. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Roberts NJ, Zhou S, Diaz LA Jr and
Holdhoff M: Systemic use of tumor necrosis factor alpha as an
anticancer agent. Oncotarget. 2:739–751. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang C, Niu J, Li M, Teng Y, Wang H and
Zhang Y: Tumor vasculature-targeted recombinant mutated human TNF-α
enhanced the antitumor activity of doxorubicin by increasing tumor
vessel permeability in mouse xenograft models. PLoS One.
9:e870362014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li M, Xu T, Zhang Z, Xue X, Zhang C, Qin
X, Li W, Hao Q, Zhang W and Zhang Y: Phase II multicenter,
randomized, double-blind study of recombinant mutated human tumor
necrosis factor-α in combination with chemotherapies in cancer
patients. Cancer Sci. 103:288–295. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kafshdooz T, Tabrizi AD, Ardabili SM
Mohaddes, Kafshdooz L, Ghojazadeh M, Gharesouran J, Abdii A and
Alizadeh H: Polymorphism of p53 gene codon 72 in endometrial
cancer: Correlation with tumor grade and histological type. Asian
Pac J Cancer Prev. 15:9603–9606. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu J, Dong H, Shen W, He S, Li H, Lu Y, Wu
ZS and Jia L: New molecular beacon for p53 gene point mutation and
significant potential in serving as the polymerization primer.
Biosens Bioelectron. 66:504–511. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nason KS: Predicting response to
neoadjuvant therapy in esophageal cancer with p53 genotyping: A
fortune-teller's crystal ball or a viable prognostic tool? J Thorac
Cardiovasc Surg. 148:2286–2287. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ji W, Zhang N, Zhang H, Ma J, Zhong H,
Jiao J and Gao Z: Expression of p53β and Δ133p53 isoforms in
different gastric tissues. Int J Clin Exp Pathol. 8:10468–10474.
2015.PubMed/NCBI
|
|
24
|
Marcel V, Fernandes K, Terrier O, Lane DP
and Bourdon JC: Modulation of p53β and p53γ expression by
regulating the alternative splicing of TP53 gene modifies cellular
response. Cell Death Differ. 21:1377–1387. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Avery-Kiejda KA, Morten B, Wong-Brown MW,
Mathe A and Scott RJ: The relative mRNA expression of p53 isoforms
in breast cancer is associated with clinical features and outcome.
Carcinogenesis. 35:586–596. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hofstetter G, Berger A, Fiegl H, Slade N,
Zorić A, Holzer B, Schuster E, Mobus VJ, Reimer D, Daxenbichler G,
et al: Alternative splicing of p53 and p73: The novel p53 splice
variant p53delta is an independent prognostic marker in ovarian
cancer. Oncogene. 29:1997–2004. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hofstetter G, Berger A, Berger R, Zorić A,
Braicu EI, Reimer D, Fiegl H, Marth C, Zeimet AG, Ulmer H, et al:
The N-terminally truncated p53 isoform Δ40p53 influences prognosis
in mucinous ovarian cancer. Int J Gynecol Cancer. 22:372–379. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hofstetter G, Berger A, Schuster E, Wolf
A, Hager G, Vergote I, Cadron I, Sehouli J, Braicu EI, Mahner S, et
al: Δ133p53 is an independent prognostic marker in p53 mutant
advanced serous ovarian cancer. Br J Cancer. 105:1593–1599. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Berglind H, Pawitan Y, Kato S, Ishioka C
and Soussi T: Analysis of p53 mutation status in human cancer cell
lines: A paradigm for cell line cross-contamination. Cancer Biol
Ther. 7:699–708. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ji W, Ma J, Zhang H, Zhong H, Li L, Ding
N, Jiao J and Gao Z: Role of p53β in the inhibition of
proliferation of gastric cancer cells expressing wild-type or
mutated p53. Mol Med Rep. 12:691–695. 2015.PubMed/NCBI
|
|
31
|
Zheng S, Zhao M, Ren Y, Wu Y and Yang J:
Sesamin suppresses STZ induced INS-1 cell apoptosis through
inhibition of NF-κB activation and regulation of Bcl-2 family
protein expression. Eur J Pharmacol. 750:52–58. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cekanova M, Fernando RI, Siriwardhana N,
Sukhthankar M, De la Parra C, Woraratphoka J, Malone C, Ström A,
Baek SJ, Wade PA, et al: BCL-2 family protein, BAD is
down-regulated in breast cancer and inhibits cell invasion. Exp
Cell Res. 331:1–102. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bourdon JC, Fernandes K, Murray-Zmijewski
F, Liu G, Diot A, Xirodimas DP, Saville MK and Lane DP: p53
isoforms can regulate p53 transcriptional activity. Genes Dev.
19:2122–2137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Khoury MP and Bourdon JC: p53 isoforms: An
intracellular microprocessor? Genes Cancer. 2:453–465. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Silden E, Hjelle SM, Wergeland L, Sulen A,
Andresen V, Bourdon JC, Micklem DR, McCormack E and Gjertsen BT:
Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity
in TP53 (null) cell lines. PLoS One. 8:e562762013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Okumura N, Yoshida H, Kitagishi Y,
Nishimura Y and Matsuda S: Alternative splicings on p53, BRCA1 and
PTEN genes involved in breast cancer. Biochem Biophys Res Commun.
413:395–399. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Marcel V, Dichtel-Danjoy ML, Sagne C,
Hafsi H, Ma D, Ortiz-Cuaran S, Olivier M, Hall J, Mollereau B,
Hainaut P and Bourdon JC: Biological functions of p53 isoforms
through evolution: Lessons from animal and cellular models. Cell
Death Differ. 18:1815–1824. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cheng P, Shi RH, Zhang HJ, Yu LZ, Zhang GX
and Hao B: Effects of tumor necrosis factor-alpha inducing
protein-alpha secreted by Helicobacter pylori on human gastric
epithelial cells. Zhonghua Yi Xue Za Zhi. 88:1528–1532. 2008.(In
Chinese). PubMed/NCBI
|
|
39
|
Fukui T, Matsui K, Kato H, Takao H,
Sugiyama Y, Kunieda K and Saji S: Significance of apoptosis induced
by tumor necrosis factor-alpha and/or interferon-gamma against
human gastric cancer cell lines and the role of the p53 gene. Surg
Today. 33:847–853. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shimoyama S, Mochizuki Y, Kusada O and
Kaminishi M: Supra-additive antitumor activity of 5FU with tumor
necrosis factor-related apoptosis-inducing ligand on gastric and
colon cancers in vitro. Int J Oncol. 21:643–648. 2002.PubMed/NCBI
|
